Zevra Therapeutics, Inc. ZVRA Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Zevra Therapeutics, Inc. (ZVRA) reported short- and long-term operating lease liabilities of -$123K in Q1 2026.
- How has Zevra Therapeutics, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- Zevra Therapeutics, Inc.'s short- and long-term operating lease liabilities increased by 35.3% year-over-year, from -$190K to -$123K.
- What is the long-term trend for Zevra Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Over 3 years (2021 to 2025), Zevra Therapeutics, Inc.'s short- and long-term operating lease liabilities has grown at a 27.5% compound annual growth rate (CAGR), from -$326K to -$675K.